GlassScriptPhysician profile
Ayman Dahman
NPI 1548364086
$2,366.71
in general payments reported to CMS, 2019-2025
28 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $105 · 2021: $249 · 2022: $301 · 2023: $345 · 2024: $324 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.92 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.47 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Astellas Pharma US INC | $265.52 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $221.00 | 2019-2022 | |
| Pfizer INC. | $215.59 | 2019-2025 | |
| Medtronic, INC. | $147.17 | 2024-2025 | V-Loc 180 |
| Hologic Sales and Service, LLC | $93.95 | 2019-2024 | Aptima |
| Organon LLC | $82.74 | 2022-2025 | Jada System, Nexplanon |
| Merck Sharp & Dohme LLC | $75.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.63 | 2019-2025 | |
| Allergan, INC. | $63.86 | 2019 | |
| Sage Therapeutics, LLC | $58.55 | 2023-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $41.79 | 2019 | |
| Myovant Sciences INC. | $41.00 | 2021 | |
| Mayne Pharma Commercial LLC | $37.07 | 2022-2025 | |
| Duchesnay USA Incorporated | $34.61 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $32.04 | 2023-2024 | Myfembree |
| Roche Diagnostics Corporation | $30.43 | 2019 | |
| Coopersurgical, INC. | $29.25 | 2020-2021 | |
| Exact Sciences Corporation | $28.07 | 2025 | |
| Amgen INC. | $20.19 | 2023 | Prolia, Evenity |
| Convatec INC. | $19.82 | 2023 | |
| Exeltis, USA INC. | $18.22 | 2025 | Slynd |
| Millicent US INC | $18.17 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Daiichi Sankyo INC. | $17.18 | 2019 | |
| Agile Therapeutics, INC. | $16.06 | 2022 | |
| Optumhealth Care Solutions, LLC | $14.41 | 2023 | Vivify Health Care Team Portal, Zyno Solutions |
| Meditrina | $13.66 | 2024 | |
| Evofem Biosciences, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Dahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.